PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 4, 1995JNCI Journal of the National Cancer Institute690 citations

Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

View Full Paper
AGAron GoldhirschWWWilliam C. WoodHSHans-Jörg Senn

Key Points

  • To summarize key discussions and recommendations from an international consensus panel on treating primary breast cancer.
  • Compilation of expert opinions from an international panel of oncologists.
  • Discussion focused on current treatment modalities and emerging therapies for primary breast cancer.
  • Agreed on several treatment recommendations to optimize patient outcomes.
  • Highlighted the importance of personalized treatment approaches in managing primary breast cancer.

Abstract

Journal Article Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer Get access Aron Goldhirsch, Aron Goldhirsch Search for other works by this author on: Oxford Academic PubMed Google Scholar William C. Wood, William C. Wood Search for other works by this author on: Oxford Academic PubMed Google Scholar Hans-Jörg Senn, Hans-Jörg Senn Search for other works by this author on: Oxford Academic PubMed Google Scholar John H. Glick, John H. Glick Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard D. Gelber Richard D. Gelber Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 19, 4 October 1995, Pages 1441–1445, https://doi.org/10.1093/jnci/87.19.1441 Published: 04 October 1995 Article history Received: 09 May 1995 Revision received: 06 July 1995 Accepted: 21 July 1995 Published: 04 October 1995

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Goldhirsch et al. (1995) studied this question.

synapsesocial.com/papers/6a0cd34217d56fa39a4a567fhttps://doi.org/10.1093/jnci/87.19.1441
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.1993 · 54 citations
  2. 2Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.1990 · 295 citations
  3. 3Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors1996 · 871 citations
  4. 4High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.1995 · 180 citations
  5. 5Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results1995 · 315 citations